Correlation of Lipid Ratios With the Severity of Pulmonary Alveolar Proteinosis: A Cross-Sectional Study

Yan, Xin; Gao, Yujuan; Zhao, Qi; Qiu, Xiaohua; Tian, Mi; Yi, Zichuan

doi:10.3389/fnut.2021.610765

Cited by 6 publications

(3 citation statements)

References 29 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has also been demonstrated that the LDL-C/HDL-C ratio is associated with PaO 2 levels and severity of pulmonary alveolar proteinosis (PAP). PAP patients had higher TC/HDL-C and TG/HDL-C than the control group [ 49 ].…”

Section: Discussionmentioning

confidence: 99%

Are lipid ratios and triglyceride-glucose index associated with critical care outcomes in COVID-19 patients?

et al. 2022

View full text Add to dashboard Cite

Lipid ratios and the triglyceride and glucose index (TyG) could be a simple biochemical marker of insulin resistance (IR). The current study was carried out to examine the correlation between triglyceride to high-density lipoprotein-cholesterol (TG/HDL-C), total cholesterol to HDL-C (TC/HDL-C), low-density lipoprotein-cholesterol to HDL-C ratio (LDL-C/HDL-C), as well as TyG index with the severity and mortality of severe coronavirus disease 2019 (COVID-19). A total of 1228 confirmed COVID-19 patients were included in the current research. Regression models were performed to evaluate the correlation between the lipid index and severity and mortality of COVID-19. The TyG index and TG/HDL-C levels were significantly higher in the severe patients (P<0.05). TG/HDL-C, LDL-C/HDL-C, TC/HDL-C ratios, and TyG index were significantly lower in survivor cases (P<0.05). Multivariate logistic regression analysis demonstrated that predictors of the severity adjusted for age, sex and BMI were TyG index, TG/HDL-C ratio (OR = 1.42 CI:1.10–1.82, OR = 1.06 CI: 1.02–1.11, respectively). This analysis showed that TG/HDL-C, TC/HDL-C, LDL-C/HDL-C ratios, and TyG index statistically are correlated with COVID-19 mortality (OR = 1.12 CI:1.06–1.18, OR = 1.24 CI:1.05–1.48, OR = 1.47 CI:1.19–1.80, OR = 1.52 CI:1.01–2.31, respectively). In summary, the TyG index and lipid ratios such as TC/HDL-C, TG/HDL-C, LDL-C/HDL-C could be used as an early indicator of COVID-19 mortality. Furthermore, the study revealed that TyG index and TG/HDL-C indices are biochemical markers of COVID-19 severe prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Are lipid ratios and triglyceride-glucose index associated with critical care outcomes in COVID-19 patients?

et al. 2022

View full text Add to dashboard Cite

show abstract

“…As to the role of lipid ratios in PAP, serum TC/HDL ratios of PAP patients were significantly higher compared to healthy subjects [ 19 ]. In addition, the level of TC/HDL-C has been reported to be positively associated with the occurrence and severity of PAP [ 20 ]. In the future, we could monitor effectiveness of statin therapy for PAP by detecting the levels of serum TC/HDL ratios.…”

Section: Discussionmentioning

confidence: 99%

Assessment of Statin Treatment for Pulmonary Alveolar Proteinosis without Hypercholesterolemia: A 12-Month Prospective, Longitudinal, and Observational Study

Shi

Gui

Ding

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Background. Pulmonary alveolar proteinosis (PAP) is a rare disorder which is characterized by the accumulation of excessive surfactant lipids and proteins in alveolar macrophages and alveoli. Oral statin therapy has been reported to be a novel therapy for PAP with hypercholesterolemia. We aimed to evaluate the safety and efficacy of oral statin therapy for PAP without hypercholesterolemia. Methods. In a prospective real-world observational study, 47 PAP patients without hypercholesterolemia were screened. Oral statin was initiated as therapy for these PAP patients with 12 months of follow-up. Results. Forty PAP patients completed the study. 26 (65%) of 40 PAP patients responded to statin therapy according to the study criteria. Partial pressure of arterial oxygen (PaO2) and percentage of diffusion capacity predicted (DLCO%) significantly increased while disease severity score (DSS) and radiographic abnormalities decreased after 12 months of statin therapy (all p < 0.05 ). The factors associated with response were higher levels of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody and baseline total cholesterol/high-density lipoprotein cholesterol (TC/HDL) ( p = 0.015 and p = 0.035 , respectively). The area under the receiver operating characteristic curve (AUROC) of dose of atorvastatin for predicting the response to statin therapy for PAP was 0.859 (95% CI: 0.738-0.979, p < 0.001 ). The cutoff dose of atorvastatin was 67.5 mg daily with their corresponding specificity (64.3%) and sensitivity (96.2%). No severe side effects were observed during the study. Conclusions. In PAP patients without hypercholesterolemia, statin therapy resulted in improvements in arterial blood gas (ABG) measurement, pulmonary function, and radiographic assessment.

show abstract

“…There are multiple inflammatory cytokines (e.g., IL-1β, IL-6, TNF-α) involved in increasing TG plasma levels and decreasing HDL-c concentrations [ 125 ]. A TG/HDL-c ratio > 3 can be considered to be a marker of systemic inflammation in IPAH [ 125 ] and a promising marker of severity progression in PAH [ 128 ]. Data are still limited regarding the role of lipid ratios in PAH.…”

Section: Metabolic Biomarkersmentioning

confidence: 99%

Biomarkers in Pulmonary Arterial Hypertension

2022

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is a severe medical condition characterized by elevated pulmonary vascular resistance (PVR), right ventricular (RV) failure, and death in the absence of appropriate treatment. The progression and prognosis are strictly related to the etiology, biochemical parameters, and treatment response. The gold-standard test remains right-sided heart catheterization, but dynamic monitoring of systolic pressure in the pulmonary artery is performed using echocardiography. However, simple and easily accessible non-invasive assays are also required in order to monitor this pathology. In addition, research in this area is in continuous development. In recent years, more and more biomarkers have been studied and included in clinical guidelines. These biomarkers can be categorized based on their associations with inflammation, endothelial cell dysfunction, cardiac fibrosis, oxidative stress, and metabolic disorders. Moreover, biomarkers can be easily detected in blood and urine and correlated with disease severity, playing an important role in diagnosis, prognosis, and disease progression.

show abstract

Correlation of Lipid Ratios With the Severity of Pulmonary Alveolar Proteinosis: A Cross-Sectional Study

Cited by 6 publications

References 29 publications

Are lipid ratios and triglyceride-glucose index associated with critical care outcomes in COVID-19 patients?

Are lipid ratios and triglyceride-glucose index associated with critical care outcomes in COVID-19 patients?

Assessment of Statin Treatment for Pulmonary Alveolar Proteinosis without Hypercholesterolemia: A 12-Month Prospective, Longitudinal, and Observational Study

Biomarkers in Pulmonary Arterial Hypertension

Contact Info

Product

Resources

About